Friday, September 11, 2020 1:59:03 PM
Why announce results while there's distribution questions up in the air? You have to remember that as an investor, your bias leads you to believe that the best course of action is what will affect the stock price in the short term. As business people, NeuroRX / Relief / Glaxo are all looking at this in much longer horizons (1 year, 3 year, 10 year) and all the uses for it. The long game is that you answer any and all outstanding questions (distribution capabilities, outstanding shares, financing structure, marketing announcements) before you drop trial data. The best path to success is one not filled with ammunition for naysayers
STAY RESILIENT
STAY RESILIENT
Recent RLFTF News
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank • ACCESS Newswire • 03/19/2026 06:35:00 AM
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics • ACCESS Newswire • 12/23/2025 06:20:00 AM
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics • ACCESS Newswire • 12/15/2025 06:20:00 AM
- Relief Therapeutics Shareholders Approve Business Combination with NeuroX • ACCESS Newswire • 11/14/2025 05:40:00 PM
- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 • ACCESS Newswire • 10/29/2025 06:20:00 AM
- Micro-Cap Biotech Skyrockets on FDA Pediatric Disease Nod • AllPennyStocks.com • 05/22/2025 04:49:00 PM
